Enoyl-ACP reductase inhibitors - Debiopharm Group/Nobelex Biotech

Drug Profile

Enoyl-ACP reductase inhibitors - Debiopharm Group/Nobelex Biotech

Alternative Names: Debio-1453; Debio-1454; FabI inhibitors - Debiopharm Group/Nobelex Biotech; Narrow-spectrum antibiotics - Debiopharm Group/ Nobelex Biotech

Latest Information Update: 25 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Debiopharm Group; Nobelex Biotech
  • Class Small molecules
  • Mechanism of Action Enoyl-ACP reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Gonorrhoea; Gram-negative infections; Helicobacter infections

Most Recent Events

  • 25 Oct 2016 Early research in Helicobacter infections in Switzerland (unspecified route) (Debiopharm Group pipeline, October 2016)
  • 26 Jun 2014 Early research in Gonorrhoea in Canada (unspecified route)
  • 26 Jun 2014 Early research in Gram-negative infections in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top